Skip to main content

Advertisement

SpringerLink
Log in

Stereotactic Body Radiotherapy for Localized Kidney Cancer

  • Kidney Diseases (G Ciancio, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Stereotactic body radiation therapy (SBRT) is increasingly utilized in the management of localized kidney cancers, particularly for patients who are not surgical candidates. Herein, we provide a narrative review of SBRT in the management of localized kidney cancers.

Recent Findings

Recent prospective studies and multi-institutional retrospective studies highlight the safety and efficacy of SBRT in the management of renal tumors, a disease previously thought to be radioresistant. Studies have shown that local control is greater than 90% with rare grade 3 or 4 toxicity and no grade 5 toxicity. SBRT can be utilized successfully in the treatment of large kidney tumors (> 5 cm). New techniques such as MRI-guided radiation therapy may further improve the therapeutic ratio. However, randomized clinical trials are necessary to confirm the optimal dosing schedule and compare outcomes with nephrectomy, which remains the standard of care in suitable patients.

Summary

Advances in SBRT have made this modality a safe and effective treatment option in the management of localized kidney cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

    Article  Google Scholar 

  2. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. https://doi.org/10.14740/wjon1279.

  3. Homma Y, Kawabe K, Kitamura T, Nishimura Y, Shinohara M, Kondo Y, et al. Increased incidental detection and reduced mortality in renal cancer–recent retrospective analysis at eight institutions. Int J Urol. 1995;2(2):77–80. https://doi.org/10.1111/j.1442-2042.1995.tb00428.x.

    Article  CAS  Google Scholar 

  4. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59(1):135–41. https://doi.org/10.1016/j.eururo.2010.10.029.

    Article  Google Scholar 

  5. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. https://doi.org/10.1016/j.eururo.2016.02.029.

    Article  Google Scholar 

  6. Williamson SR, Gill AJ, Argani P, Chen YB, Egevad L, Kristiansen G, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44(7):e47–65. https://doi.org/10.1097/PAS.0000000000001476.

    Article  Google Scholar 

  7. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. https://doi.org/10.1016/j.eururo.2019.02.011.

    Article  Google Scholar 

  8. Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611–23 e17. https://doi.org/10.1016/j.cell.2018.02.020.

  9. Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–61. https://doi.org/10.1038/s41581-020-00359-2.

    Article  CAS  Google Scholar 

  10. Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin Cancer Res. 2018;24(18):4407–15. https://doi.org/10.1158/1078-0432.CCR-18-0323.

    Article  CAS  Google Scholar 

  11. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol. 2016;195(1):180–7. https://doi.org/10.1016/j.juro.2015.07.113.

    Article  CAS  Google Scholar 

  12. Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36(9):1341–53. https://doi.org/10.1007/s00345-018-2286-7.

    Article  Google Scholar 

  13. Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014;48(3):231–8. https://doi.org/10.3109/21681805.2013.864698.

    Article  Google Scholar 

  14. Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5): e035938. https://doi.org/10.1136/bmjopen-2019-035938.

    Article  Google Scholar 

  15. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: Part I. J Urol. 2021;206(2):199–208. https://doi.org/10.1097/JU.0000000000001911.

    Article  Google Scholar 

  16. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(5):706–20. https://doi.org/10.1093/annonc/mdz056.

    Article  CAS  Google Scholar 

  17. Motzer RJ, Jonasch, E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A (2022) Kidney Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Nat Comprehen Cancer Net 20(1):71–90.

  18. DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol. 1997;158(3 Pt 1):746–9. https://doi.org/10.1097/00005392-199709000-00013.

    Article  CAS  Google Scholar 

  19. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7. https://doi.org/10.1016/S1470-2045(13)70569-2.

    Article  Google Scholar 

  20. Champion KJ, Guinea M, Dammai V, Hsu T. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res. 2008;68(12):4649–57. https://doi.org/10.1158/0008-5472.CAN-07-6003.

    Article  CAS  Google Scholar 

  21. Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009;115(10 Suppl):2282–9. https://doi.org/10.1002/cncr.24238.

    Article  CAS  Google Scholar 

  22. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https://doi.org/10.1038/nrdp.2017.9.

    Article  Google Scholar 

  23. Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol. 2020;8:41. https://doi.org/10.3389/fcell.2020.00041.

    Article  Google Scholar 

  24. Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014;19(4):570–8. https://doi.org/10.1007/s10147-014-0717-z.

    Article  CAS  Google Scholar 

  25. Song CW, Lee YJ, Griffin RJ, Park I, Koonce NA, Hui S, et al. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys. 2015;93(1):166–72. https://doi.org/10.1016/j.ijrobp.2015.05.016.

    Article  Google Scholar 

  26. Ketteler J, Wittka A, Leonetti D, Roy VV, Estephan H, Maier P, et al. Caveolin-1 regulates the ASMase/ceramide-mediated radiation response of endothelial cells in the context of tumor-stroma interactions. Cell Death Dis. 2020;11(4):228. https://doi.org/10.1038/s41419-020-2418-z.

    Article  Google Scholar 

  27. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9. https://doi.org/10.1126/science.1082504.

    Article  CAS  Google Scholar 

  28. Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, et al. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J Biol Chem. 2000;275(12):8657–63. https://doi.org/10.1074/jbc.275.12.8657.

    Article  CAS  Google Scholar 

  29. • Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2020;117(38):23721–9. https://doi.org/10.1073/pnas.2001933117. This preclinical study demonstrates the ability of radiation therapy to activate the adaptive immune response in renal cell carcinoma suggesting a possible synergy between radiation and the immune system that could be exploited with immunotherapy.

    Article  CAS  Google Scholar 

  30. Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–8. https://doi.org/10.1016/j.ijrobp.2011.02.040.

    Article  Google Scholar 

  31. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34. https://doi.org/10.1186/1748-717X-6-34.

    Article  Google Scholar 

  32. Haque W, Verma V, Lewis GD, Lo SS, Butler EB, Teh BS. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol. 2018;14(9):819–27. https://doi.org/10.2217/fon-2017-0536.

    Article  CAS  Google Scholar 

  33. Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 2016;12(5):637–45. https://doi.org/10.2217/fon.16.2.

    Article  CAS  Google Scholar 

  34. Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother Oncol. 2016;118(3):540–6. https://doi.org/10.1016/j.radonc.2016.01.027.

    Article  Google Scholar 

  35. Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017;120(5):623–30. https://doi.org/10.1111/bju.13811.

    Article  Google Scholar 

  36. Staehler M, Schuler T, Spek A, Rodler S, Tamalunas A, Furweger C, et al. Propensity score-matched analysis of single fraction robotic radiosurgery versus open partial nephrectomy in renal cell carcinoma: oncological outcomes. Cureus. 2022;14(1): e21623. https://doi.org/10.7759/cureus.21623.

    Article  Google Scholar 

  37. • Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L, et al. Stereotactic ablative radiotherapy for >/=T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys. 2020;108(4):941–9. https://doi.org/10.1016/j.ijrobp.2020.06.014. This large, international study from the IROCK consortioum demonstrates the safety and efficacy of SBRT in patients with large, primary renal cell carcinomas.

    Article  Google Scholar 

  38. Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934–42. https://doi.org/10.1002/cncr.31156.

    Article  Google Scholar 

  39. Hanzly M, Creighton T, Mix M, Zeeck K, Fung-Kee-Fung S, Singh AK, et al. Stereotactic body radiotherapy for the treatment of renal tumors. Urol Case Rep. 2014;2(5):147–9. https://doi.org/10.1016/j.eucr.2014.05.011.

    Article  Google Scholar 

  40. Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T, et al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys. 2014;90(5):1061–8. https://doi.org/10.1016/j.ijrobp.2014.07.043.

    Article  Google Scholar 

  41. Peddada AV, Anderson D, Blasi OC, McCollough K, Jennings SB, Monroe AT. Nephron-sparing robotic radiosurgical therapy for primary renal cell carcinoma: single-institution experience and review of the literature. Adv Radiat Oncol. 2020;5(2):204–11. https://doi.org/10.1016/j.adro.2019.10.001.

    Article  Google Scholar 

  42. • Grubb WR, Ponsky L, Lo SS, Kharouta M, Traughber B, Sandstrom K, et al. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol. 2021;155:138–43. https://doi.org/10.1016/j.radonc.2020.10.031. This multi-insitutional phase I dose escalation trial demonstrated that SBRT up to a dose of 60 Gy in 3 fractions is well-tolerated for patients with localized renal cell carcinoma.

    Article  CAS  Google Scholar 

  43. Sun MR, Brook A, Powell MF, Kaliannan K, Wagner AA, Kaplan ID, et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. AJR Am J Roentgenol. 2016;206(3):544–53. https://doi.org/10.2214/AJR.14.14099.

    Article  Google Scholar 

  44. Kaidar-Person O, Price A, Schreiber E, Zagar TM, Chen RC. Stereotactic body radiotherapy for large primary renal cell carcinoma. Clin Genitourin Cancer. 2017;15(5):e851–4. https://doi.org/10.1016/j.clgc.2017.03.012.

    Article  Google Scholar 

  45. Senger C, Conti A, Kluge A, Pasemann D, Kufeld M, Acker G, et al. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function. BMC Urol. 2019;19(1):96. https://doi.org/10.1186/s12894-019-0531-z.

    Article  CAS  Google Scholar 

  46. Grozman V, Onjukka E, Wersall P, Lax I, Tsakonas G, Nyren S, et al. Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects. Acta Oncol. 2021;60(3):305–11. https://doi.org/10.1080/0284186X.2020.1866776.

    Article  CAS  Google Scholar 

  47. Chang JH, Cheung P, Erler D, Sonier M, Korol R, Chu W. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience. Clin Oncol (R Coll Radiol). 2016;28(9):e109–14. https://doi.org/10.1016/j.clon.2016.04.002.

    Article  CAS  Google Scholar 

  48. Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, Wel AMV, et al. The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer. Cancers (Basel). 2020;12(10). https://doi.org/10.3390/cancers12102763.

  49. Correa RJM, Rodrigues GB, Chen H, Warner A, Ahmad B, Louie AV. Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations. Am J Clin Oncol. 2018;41(6):568–75. https://doi.org/10.1097/COC.0000000000000329.

    Article  Google Scholar 

  50. Blitzer GC, Wojcieszynski A, Abel EJ, Best S, Lee FT Jr, Hinshaw JL, et al. Combining stereotactic body radiotherapy and microwave ablation appears safe and feasible for renal cell carcinoma in an early series. Clin Genitourin Cancer. 2021;19(5):e313–8. https://doi.org/10.1016/j.clgc.2021.04.010.

    Article  Google Scholar 

  51. Grelier L, Baboudjian M, Gondran-Tellier B, Couderc AL, McManus R, Deville JL, et al. Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience. Cancers (Basel). 2021;13(13). https://doi.org/10.3390/cancers13133129.

  52. Funayama S, Onishi H, Kuriyama K, Komiyama T, Marino K, Araya M, et al. Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy. Technol Cancer Res Treat. 2019;18:1533033818822329. https://doi.org/10.1177/1533033818822329.

    Article  Google Scholar 

  53. Yamamoto T, Kawasaki Y, Umezawa R, Kadoya N, Matsushita H, Takeda K, et al. Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. J Radiat Res. 2021;62(3):533–9. https://doi.org/10.1093/jrr/rrab031.

    Article  Google Scholar 

  54. Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R, et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol. 2015;117(1):183–7. https://doi.org/10.1016/j.radonc.2015.08.030.

    Article  Google Scholar 

  55. Uhlig A, Uhlig J, Trojan L, Kim HS. Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol. 2020;31(4):564–71. https://doi.org/10.1016/j.jvir.2019.11.009.

    Article  Google Scholar 

  56. Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019;37(14):1209–16. https://doi.org/10.1200/JCO.18.01074.

    Article  CAS  Google Scholar 

  57. Yamamoto T, Kadoya N, Takeda K, Matsushita H, Umezawa R, Sato K, et al. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. Radiat Oncol. 2016;11:72. https://doi.org/10.1186/s13014-016-0651-5.

    Article  CAS  Google Scholar 

  58. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35(1):310–7. https://doi.org/10.1118/1.2818738.

    Article  Google Scholar 

  59. Sonier M, Chu W, Lalani N, Erler D, Cheung P, Korol R. Implementation of a volumetric modulated arc therapy treatment planning solution for kidney and adrenal stereotactic body radiation therapy. Med Dosim. 2016;41(4):323–8. https://doi.org/10.1016/j.meddos.2016.09.001.

    Article  Google Scholar 

  60. Baydoun A, Vapiwala N, Ponsky LE, Awan M, Kassaee A, Sutton D, et al. Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning. J Appl Clin Med Phys. 2018. https://doi.org/10.1002/acm2.12308.

    Article  Google Scholar 

  61. Frick MA, Chhabra AM, Lin L, Simone CB 2nd. First ever use of proton stereotactic body radiation therapy delivered with curative intent to bilateral synchronous primary renal cell carcinomas. Cureus. 2017;9(10): e1799. https://doi.org/10.7759/cureus.1799.

    Article  Google Scholar 

  62. Pham D, Kron T, Foroudi F, Siva S. Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: a case study. Med Dosim. 2013;38(3):304–8. https://doi.org/10.1016/j.meddos.2013.03.001.

    Article  Google Scholar 

  63. Gaudreault M, Siva S, Kron T, Hardcastle N. Reducing the impact on renal function of kidney SABR through management of respiratory motion. Phys Med. 2021;89:72–9. https://doi.org/10.1016/j.ejmp.2021.07.020.

    Article  Google Scholar 

  64. Siva S, Pham D, Gill S, Bressel M, Dang K, Devereux T, et al. An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiat Oncol. 2013;8:248. https://doi.org/10.1186/1748-717X-8-248.

    Article  Google Scholar 

  65. Chevli N, Chiang SB, Farach AM, Haque W, Satkunasivam R, Bernicker EH, et al. DMSA-SPECT: a novel approach to nephron sparing SBRT for renal cell carcinoma. Adv Radiat Oncol. 2021;6(6): 100719. https://doi.org/10.1016/j.adro.2021.100719.

    Article  Google Scholar 

  66. Prins FM, Stemkens B, Kerkmeijer LGW, Barendrecht MM, de Boer HJ, Vonken EPA, et al. Intrafraction motion management of renal cell carcinoma with magnetic resonance imaging-guided stereotactic body radiation therapy. Pract Radiat Oncol. 2019;9(1):e55–61. https://doi.org/10.1016/j.prro.2018.09.002.

    Article  Google Scholar 

  67. Stemkens B, Glitzner M, Kontaxis C, de Senneville BD, Prins FM, Crijns SPM, et al. Effect of intra-fraction motion on the accumulated dose for free-breathing MR-guided stereotactic body radiation therapy of renal-cell carcinoma. Phys Med Biol. 2017;62(18):7407–24. https://doi.org/10.1088/1361-6560/aa83f7.

    Article  Google Scholar 

  68. Kutuk T, McCulloch J, Mittauer KE, Romaguera T, Alvarez D, Gutierrez AN, et al. Daily online adaptive magnetic resonance image (MRI) guided stereotactic body radiation therapy for primary renal cell cancer. Med Dosim. 2021;46(3):289–94. https://doi.org/10.1016/j.meddos.2021.02.008.

    Article  Google Scholar 

  69. Aronowitz J, Ding L, Yates J, Zong Y, Zheng L, Jiang Z, et al. Stereotactic body radiotherapy for palliation of hematuria arising from urothelial carcinoma of the kidney in unfavorable surgical candidates. Am J Clin Oncol. 2021;44(5):175–80. https://doi.org/10.1097/COC.0000000000000801.

    Article  CAS  Google Scholar 

  70. Nikolaev A, Benda R. Palliative radiation therapy for symptomatic control of inoperable renal cell carcinoma. Urol Case Rep. 2016;4:51–2. https://doi.org/10.1016/j.eucr.2015.09.006.

    Article  Google Scholar 

  71. Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2013;31(2):259–63. https://doi.org/10.1016/j.urolonc.2010.11.017.

    Article  Google Scholar 

  72. Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, et al. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther. 2015;16(5):657–61. https://doi.org/10.1080/15384047.2015.1026506.

    Article  CAS  Google Scholar 

  73. Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, et al. Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial. Int J Radiat Oncol Biol Phys. 2021;110(4):1135–42. https://doi.org/10.1016/j.ijrobp.2021.01.054.

    Article  Google Scholar 

  74. Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019;5(6):958–69. https://doi.org/10.1016/j.euf.2019.06.002.

    Article  Google Scholar 

  75. Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, et al. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer. 2018;18(1):1030. https://doi.org/10.1186/s12885-018-4916-2.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

    Benjamin J. Rich & Alan Dal Pra

  2. Albany Medical College, Albany, NY, USA

    Miguel Angel Noy

Authors
  1. Benjamin J. Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Angel Noy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan Dal Pra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Dal Pra.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Kidney Diseases

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rich, B.J., Noy, M.A. & Dal Pra, A. Stereotactic Body Radiotherapy for Localized Kidney Cancer. Curr Urol Rep 23, 371–381 (2022). https://doi.org/10.1007/s11934-022-01125-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-022-01125-6

Keywords

Search

Navigation